专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20150275302A1 DETERMINATION OF SINGLE NUCLEOTIDE POLYMORPHISMS USEFUL TO PREDICT RESPONSE FOR RASAGILINE 审中-公开
标题翻译：单核细胞多态性的确定用于RASAGILINE的预测反应
公开(公告)号：US20150275302A1
公开(公告)日：2015-10-01
申请号：US14674606
申请日：2015-03-31
申请人： Mario Masellis , Joanne Knight , Maureen Shannon Collinson , Anthony Edward Lang , James Lowery Kennedy , Joseph Levy , Amir Tchelet , Iris Grossman , Eli Eyal , Ofra Barnett
发明人： Mario Masellis , Joanne Knight , Maureen Shannon Collinson , Anthony Edward Lang , James Lowery Kennedy , Joseph Levy , Amir Tchelet , Iris Grossman , Eli Eyal , Ofra Barnett
IPC分类号： C12Q1/68 , A61K45/06 , A61K31/4985 , A61K31/48 , A61K31/198 , A61K31/4045 , A61K31/428 , A61K31/381 , A61K31/135 , A61K31/439
CPC分类号： C12Q1/6883 , A61K31/135 , A61K31/198 , A61K31/381 , A61K31/4045 , A61K31/428 , A61K31/439 , A61K31/48 , A61K31/4985 , A61K45/06 , C12Q2600/106 , C12Q2600/156 , A61K2300/00
摘要： This application provides a method for treating a human subject afflicted with Parkinson's disease (PD) with a pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and a pharmaceutically acceptable carrier, comprising the steps of: (i) obtaining a biological sample comprising a genome from the human subject afflicted with Parkinson's disease; (ii) assaying the DNA or RNA of the biological sample from the human subject using a probe or a primer, to determine the diploid genotype of the human subject at single nucleotide polymorphism (SNP) rs1076560 or rs2283265; (iii) identifying the human subject as a predicted responder to rasagiline if the diploid genotype is CC at rs1076560, CC at rs2283265, or CC at both rs1076560 and rs2283265; and (iv) administering the pharmaceutical composition comprising rasagiline and a pharmaceutically acceptable carrier to the human subject if the human subject is identified as a predicted responder to rasagiline.
摘要翻译：本申请提供了用药物组合物治疗患有帕金森病（PD）的人类受试者的方法，所述药物组合物包含雷沙吉兰或雷沙吉兰的药学上可接受的盐和药学上可接受的载体，包括以下步骤：（i）获得包含来自人类受试者患有帕金森病的基因组; （ii）使用探针或引物从人受试者测定生物样品的DNA或RNA，以确定单核苷酸多态性（SNP）rs1076560或rs2283265处人受试者的二倍体基因型; （iii）如果二倍体基因型是rs1076560的CC，rs2283265的CC或rs1076560和rs2283265的CC，则将人受试者鉴定为雷沙吉兰的预测应答者; 和（iv）如果人类受试者被鉴定为雷沙吉兰的预测应答者，则向人类受试者施用包含雷沙吉兰和药学上可接受的载体的药物组合物。

IPRDB

热门服务

关于我们

友情链接

联系方式